JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on the Pharmacology and Therapeutic Applications of Veligrotug-vvze for the Treatment of Thyroid Eye Disease

Edward Raju Gope*, Siva Satya Subrahmanyam Amudalapalli, Varshini Naga Priya Gudavalli, Sri Vardhan Labala, Sowmya Nelapati, Satya Sri Thonta

Department of Pharmaceutical Analysis, KGRL College of Pharmacy, Bhimavaram, Andhra Pradesh, India

Publication history: Received on 23nd May 2026; Revised on 28th June 2026; Accepted on 30th June 2026

Article DOI: 10.69613/40tw2q27

Abstract: Thyroid eye disease is a debilitating autoimmune disorder of the orbit characterized by soft-tissue expansion, proptosis, diplopia, and progressive tissue remodeling. The pathogenesis is driven by an autoimmune interaction involving the insulin-like growth factor-1 receptor and thyroid-stimulating hormone receptor complex on orbital fibroblasts, initiating intracellular signaling cascades that promote hyaluronan accumulation, adipogenesis, and interstitial edema. Traditional interventions, consisting primarily of high-dose systemic corticosteroids, external orbital irradiation, and rehabilitative surgical decompression, show variable clinical responses and frequently fail to alter underlying tissue expansion or long-term fibrotic sequelae. Veligrotug-vvze is a targeted humanized immunoglobulin G1 kappa monoclonal antibody designed as a full antagonist of the insulin-like growth factor-1 receptor. Through selective receptor occupancy, veligrotug-vvze blocks ligand autophosphorylation and disrupts downstream phosphoinositide 3-kinase/protein kinase B and mitogen-activated protein kinase signaling cascades, terminating fibroblast differentiation and extracellular matrix expansion. The clinical development program, evaluated across pivotal phase III clinical trials including THRIVE and THRIVE-2, established therapeutic efficacy across both active and chronic disease states. Administered as a condensed regimen of five intravenous infusions at three-week intervals, veligrotug-vvze achieves clinically meaningful reductions in proptosis, improvements in diplopia, and attenuation of inflammatory indices. Adverse events require clinical vigilance, particularly regarding glycemic control, otologic monitoring for auditory disturbances, and screening for inflammatory bowel disease. Veligrotug-vvze is a refined, targeted biological paradigm that alters orbital tissue dynamics across distinct stages of thyroid eye disease.

Keywords: Veligrotug-vvze; Insulin-Like Growth Factor-1 Receptor; Thyroid Eye Disease; Graves Orbitopathy; Proptosis.

1. Introduction

Thyroid eye disease represents the primary extrathyroidal manifestation associated with autoimmune thyroid pathology, occurring predominantly in the setting of Graves' hyperthyroidism, though occasionally presenting in euthyroid or hypothyroid individuals [1]. The condition is marked by an autoimmune cascade directed against orbital connective tissue components, resulting in chronic inflammation, pathological tissue expansion, and retrobulbar remodeling [2]. Clinical features range from eyelid retraction, lagophthalmos, conjunctival hyperemia, and periorbital edema to severe, sight-threatening sequelae such as exposure keratopathy, progressive disfiguring proptosis, restrictive strabismus with debilitating diplopia, and compressive dysthyroid optic neuropathy [3]. The physical disfigurement combined with functional visual impairment imposes a profound psychosocial burden, resulting in reduced quality of life, loss of functional independence, and elevated rates of depression [4].

The natural history of the condition classically follows Rundle's curve, characterized by an initial active inflammatory phase lasting eighteen to thirty-six months, followed by a plateau and an inactive, stable fibrotic phase [5]. During the active phase, retro-orbital fibroblasts, which express both the thyroid-stimulating hormone receptor and the insulin-like growth factor-1 receptor, are stimulated by circulating autoantibodies [6]. This molecular activation induces the proliferation of orbital fibroblasts and promotes their differentiation into mature adipocytes or collagen-secreting myofibroblasts [7]. Activated fibroblasts secrete substantial quantities of hydrophilic glycosaminoglycans, primarily hyaluronan [8]. Due to its high osmotic capacity, hyaluronan binds large volumes of water, producing massive edema within the unyielding bony orbital space [9]. This process drives forward globe protrusion, impedes venous outflow, elevates intraorbital pressure, and restricts extraocular muscle motility [10].

* Corresponding author: Edward Raju Gope

Historically, therapeutic strategies for moderate-to-severe active disease relied on broad-spectrum immunosuppression [11]. Intravenous pulse glucocorticoids remain a primary initial strategy, aimed at curbing orbital inflammation during the active phase [12]. However, systemic corticosteroid therapy shows limited efficacy in resolving established proptosis or persistent diplopia, which stem directly from expanded orbital adipose tissue and muscular enlargement [13]. High-dose steroid regimens carry substantial risks of systemic toxicity, including hepatic dysfunction, metabolic dysregulation, secondary osteoporosis, Cushingoid features, hypertension, and opportunistic infections [14]. Furthermore, a meaningful proportion of treated patients experience disease rebound upon steroid cessation or exhibit intrinsic glucocorticoid resistance [15].

Non-pharmacological modalities, such as external beam orbital radiation, offer localized anti-inflammatory benefit by targeting radio-sensitive infiltrating lymphocytes, but radiation fails to reverse retro-orbital mechanical expansion and carries concerns regarding radiation-induced retinopathy or secondary malignancy [16]. Consequently, rehabilitative orbital decompression, strabismus surgery, and eyelid repositioning have historically been deferred to the inactive, fibrotic stage, requiring patients to endure years of disfigurement and visual deficit prior to structural correction [17]. These clinical limitations established the imperative for targeted biological therapies capable of interrupting specific molecular drivers of orbital tissue remodeling across both active and established disease phases [18]. Characterization of the functional synergy between the thyroid-stimulating hormone receptor and the insulin-like growth factor-1 receptor marked a pivotal transition in translational orbital therapeutics [19]. Because the insulin-like growth factor-1 receptor is heavily overexpressed on orbital fibroblasts and immune cells in affected patients, its physical and functional coupling with thyroid-stimulating hormone receptors creates an interdependent signaling nexus [20]. Blocking this pathway prevents pathogenic downstream signaling cascades independently of circulating autoantibody concentrations [21].

Veligrotug-vvze emerged as a humanized monoclonal antibody engineered specifically to achieve complete antagonistic occupancy of the insulin-like growth factor-1 receptor [22]. By terminating the signaling pathways that govern orbital hyaluronan production and adipogenesis, veligrotug-vvze addresses the core pathophysiological mechanisms driving tissue expansion [23]. Regulatory milestones culminated in its approval by the United States Food and Drug Administration, establishing a targeted biological option with an abbreviated, five-dose infusion schedule effective in both active and chronic presentations of thyroid eye disease [24].

2. Molecular Target and Mechanism of Action

2.1. The IGF-1R and TSHR Signaling Network in Orbital Remodeling

Orbital fibroblasts derived from patients with Graves' orbitopathy exhibit distinct biological characteristics compared to non-orbital connective tissue cells [25]. Central to this distinction is the heightened density of the insulin-like growth factor-1 receptor, a heterotetrameric transmembrane receptor tyrosine kinase comprising two extracellular alpha subunits and two intracellular beta subunits containing intrinsic tyrosine kinase domains [26]. On the orbital fibroblast membrane, the insulin-like growth factor-1 receptor forms a macromolecular signaling complex with the thyroid-stimulating hormone receptor, a seven-transmembrane G-protein-coupled receptor [27].

Autoantibodies directed against the thyroid-stimulating hormone receptor, designated as thyroid-stimulating immunoglobulins, engage the receptor and initiate crosstalk with adjacent insulin-like growth factor-1 receptors [28]. This transactivation stimulates autophosphorylation of the beta subunits of the tyrosine kinase receptor, triggering intracellular cascades even in the absence of elevated endogenous growth factors [29]. The cooperative signaling between these receptors is obligatory for full pathogenic execution; inhibiting the kinase receptor effectively silences downstream signals provoked by thyroid-stimulating immunoglobulins, highlighting the central role of this complex in orbital pathology [30].

2.2. Receptor Antagonism and Signal Transduction Interruption

Veligrotug-vvze functions as a high-affinity, fully antagonistic humanized monoclonal antibody directed against the extracellular alpha subunits of the insulin-like growth factor-1 receptor [31]. Upon binding, the antibody sterically hinders the attachment of both endogenous ligands, insulin-like growth factor-1 and insulin-like growth factor-2, while simultaneously stabilizing the receptor in an inactive configuration that suppresses auto-phosphorylation of cytoplasmic tyrosine residues [32].

This complete blockade arrests the recruitment of insulin receptor substrate adapters, thereby extinguishing downstream signal propagation through the phosphoinositide 3-kinase/protein kinase B pathway and the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway [33]. The attenuation of protein kinase B activation prevents downstream phosphorylation events essential for cellular survival, transcription factor regulation, and metabolic upregulation in disease-primed orbital fibroblasts [34].

2.3. Modulation of Cellular Phenotypes and Extracellular Matrix Deposition

The cellular consequences of downstream signaling blockade directly counter the mechanical causes of orbital expansion [35]. In orbital fibroblasts, inhibition of the phosphoinositide 3-kinase pathway leads to marked downregulation of hyaluronan synthase-2, the enzyme responsible for the linear synthesis of massive hyaluronic acid polymers [36]. Suppression of hyaluronan release

decreases the interstitial osmotic gradient, resolving localized fluid retention and soft-tissue edema within the extraocular muscles and retrobulbar adipose compartments [37].



Figure 1. IGF-1R/TSHR crosstalk and mechanism of action of veligrotug-vvze.

Thyroid-stimulating immunoglobulins (TSAb) and endogenous growth factors (IGF-1/2) bind their respective receptors on human orbital fibroblasts, driving functional crosstalk. Downstream activation of PI3K/Akt and MAPK/ERK pathways promotes hyaluronan synthase-2 expression and adipogenic differentiation, causing retro-orbital edema, fat expansion, proptosis, and diplopia. Veligrotug-vvze acts as a full antagonist of IGF-1R, disrupting this signaling cascade.

Veligrotug-vvze suppresses the expression of peroxisome proliferator-activated receptor gamma, the master transcriptional regulator of adipocyte differentiation [38]. By arresting de novo orbital lipogenesis, the biological agent prevents the accumulation of newly formed lipid-laden adipocytes [39]. In parallel, attenuation of extracellular signal-regulated kinase cascades diminishes the secretion of pro-inflammatory cytokines, including interleukin-6, interleukin-8, and regulated on activation, normal T-cell expressed and secreted (RANTES), thereby dismantling the pro-inflammatory loop that recruits peripheral immune cells to the orbital space [40]. Through these coordinated cellular mechanisms, targeted antagonism reduces retro-orbital tissue volume, halts extraocular muscle swelling, and facilitates the clinical resolution of proptosis and diplopia [41].

3. Discovery, Structure, and Formulation of Veligrotug-vvze

3.1 Molecular Architecture and Bioprocessing

Veligrotug-vvze is an engineered, humanized immunoglobulin G1 kappa monoclonal antibody developed through recombinant DNA technology utilizing mammalian host systems, specifically cultured Chinese hamster ovary cell lines [42]. The antibody comprises two identical heavy chains linked via interchain disulfide bridges to two identical kappa light chains, yielding a calculated molecular weight of approximately 150 kilodaltons [43]. The variable domains are optimized through complementarity-determining region grafting and structure-guided affinity maturation, imparting high target selectivity for the extracellular alpha-subunit of the

human insulin-like growth factor-1 receptor [44]. Importantly, the antibody exhibits negligible binding affinity toward the structural homolog human insulin receptor, preserving essential insulin-dependent metabolic functions [45].

3.2 Pharmaceutical Formulation and Physicochemical Properties

The commercial therapeutic product is supplied as a sterile, non-pyrogenic, preservative-free solution formulated for intravenous administration following dilution [46]. The formulation is presented in single-dose clear glass vials containing 500 mg of veligrotug-vvze in a 10 mL volume, establishing a nominal concentration of 50 mg/mL [47]. The physicochemical stability of the monoclonal antibody is maintained through an aqueous buffer system balanced to a target pH of approximately 5.5 [48].

The inactive constituents in each 10 mL vial include:

- Histidine (6.50 mg) and L-histidine hydrochloride monohydrate (33.1 mg), serving as the primary buffering pair to maintain solution stability and prevent protein degradation.
- Sucrose (800 mg), acting as a non-reducing disaccharide lyoprotectant and tonicity modifier that limits protein aggregation.
- L-Methionine (14.9 mg), functioning as an antioxidant excipient to prevent oxidative modification of vulnerable amino acid residues.
- Polysorbate 80 (2.0 mg), acting as a non-ionic surfactant to prevent interfacial adsorption and agitation-induced particulate formation.
- Water for Injection, in quantity sufficient to achieve 10 mL.

The solution presents as clear to slightly opalescent, with a colorless to pale brownish-yellow appearance [49]. Proper storage mandates refrigeration at temperatures between 2°C and 8°C in the original commercial carton to protect the formulation from direct light exposure [50]. Freezing or excessive mechanical agitation must be avoided to prevent protein denaturation and aggregation [51].

4. Pharmacodynamics and Pharmacokinetics

4.1. Absorption and Systemic Distribution Dynamics

Because veligrotug-vvze is administered exclusively via intravenous infusion, systemic bioavailability is complete at 100% [52]. Peak serum concentrations are attained immediately at the conclusion of the intravenous infusion [53]. The systemic disposition of the drug is characterized by a two-compartment open kinetic model typical of intact therapeutic IgG1 antibodies [54].

The central volume of distribution is calculated at approximately 2.80 liters, and the peripheral volume of distribution is estimated at 2.50 liters, establishing a steady-state volume of distribution of roughly 5.30 liters in an average adult [55]. This restricted volume indicates that the distribution of veligrotug-vvze is primarily confined to the intravascular and functional interstitial fluid compartments, with modest partitioning into deep tissues prior to target-mediated equilibration within the orbital microenvironment [56].

Table 1. Pharmacokinetics of Veligrotug-vvze

Parameter	Pharmacokinetics
Absolute Bioavailability	100% (Direct Intravenous Infusion)
Central Volume of Distribution	2.80 L
Peripheral Volume of Distribution	2.50 L
Total Steady-State Distribution	5.30 L (Restricted Vascular/Intercellular Space)
Systemic Linear Clearance	0.216 L/day
Terminal Elimination Half-Life	Approximately 18 Days
Primary Elimination Route	Non-CYP, Proteolytic Catabolic Degradation
Approved Dosing Regimen	10 mg/kg IV every 3 weeks (Total 5 infusions)

4.2. Biotransformation and Clearance

As a large biological macromolecule, veligrotug-vvze does not undergo biotransformation via hepatic cytochrome P450 enzymes, nor is it eliminated through renal glomerular filtration or traditional biliary mechanisms [57]. Instead, the clearance of the antibody

proceeds through general non-specific pinocytosis followed by lysosomal proteolytic degradation into basic peptide fragments and constituent amino acids, which are subsequently recycled into the endogenous amino acid pool [58].

Clearance occurs via both linear catabolic pathways and target-mediated drug disposition mediated by the neonatal Fc receptor (FcRn) recycling mechanism [59]. The systemic linear clearance rate is estimated at 0.216 liters per day [60]. The terminal elimination half-life is approximately eighteen days [61]. This prolonged residence time sustains therapeutic receptor occupancy across the three-week dosing interval, facilitating the abbreviated five-dose treatment regimen [62]. Table 1 provides the clinical values and pharmacokinetic metrics of veligrotug-vvze in adult patients with thyroid eye disease.

4.3. Pharmacodynamic Properties and Receptor Occupancy

Direct binding of veligrotug-vvze to the extracellular domain of the insulin-like growth factor-1 receptor produces an immediate concentration-dependent neutralization of receptor activation [63]. In non-clinical studies, therapeutic levels of the antibody achieve complete inhibition of ligand-induced autophosphorylation of the beta subunits and suppress Akt phosphorylation at the cellular level [64]. Target engagement disrupts the regulatory feedback mechanisms that govern growth hormone and insulin-like growth factor homeostatic loops, frequently yielding a compensatory, transient elevation of circulating total insulin-like growth factor-1 levels up to 2.5-fold above baseline without concomitant receptor activation [65]. This elevation serves as a systemic biomarker of successful receptor saturation and pathway antagonism [66].

4.4. Special Populations and Extrinsic Covariates

Population pharmacokinetic evaluations conducted across diverse clinical cohorts indicate that age (ranging from 20 to 79 years), sex, and racial background exert no clinically relevant impact on the systemic clearance or volume of distribution of veligrotug-vvze [67]. Although body weight influences pharmacokinetic parameters resulting in higher clearance and volume of distribution in individuals with larger mass weight-based dosing at 10 mg per kilogram normalizes drug exposure across the full weight spectrum (41 kg to 161 kg) [68]. Consequently, no empirical dose modifications are indicated on the basis of age, sex, race, or mild-to-moderate renal or hepatic impairment [69].

5. Clinical Efficacy and Phase III Trials

5.1. Clinical Trials: THRIVE and THRIVE-2

The clinical efficacy and therapeutic safety profile of veligrotug-vvze were evaluated in two multicenter, randomized, double-masked, placebo-controlled phase III trials designated as THRIVE and THRIVE-2 [70]. The THRIVE study investigated the therapeutic response in patients with moderate-to-severe active thyroid eye disease, defined by a Clinical Activity Score of three or greater on a seven-point scale and symptom duration of less than nine months [71]. The THRIVE-2 study assessed patients presenting with chronic, inactive disease characterized by stable, long-standing proptosis, a Clinical Activity Score of one or zero, and disease duration exceeding twelve months [72].

Across both protocols, eligible participants were randomized in a 2:1 ratio to receive either veligrotug-vvze at 10 mg per kilogram or matching placebo administered intravenously every three weeks for a total of five infusions over twelve weeks [73]. The primary efficacy endpoint was the proptosis response rate at Week 12, defined as the proportion of patients achieving a minimum reduction of 2 millimeters in proptosis in the study eye from baseline, in the absence of a corresponding 2-millimeter deterioration in the fellow eye [74]. The important secondary endpoints encompassed overall response rate, diplopia response rate (defined as a minimum one-grade improvement on the Gorman scale in patients with baseline diplopia), changes in the mean Clinical Activity Score, and health-related quality of life metrics measured using the Graves' Ophthalmopathy Quality of Life (GO-QOL) questionnaire [75]. Table 2 provides a comparison of pivotal Phase III efficacy endpoints across active (THRIVE) and chronic (THRIVE-2) thyroid eye disease trial cohorts.

Table 2. Endpoints of Phase III Trials

Parameter / Endpoint	THRIVE (Active Disease)	THRIVE-2 (Chronic Disease)
Patient Cohort	Active TED (CAS ≥ 3)	Chronic TED (CAS 0–1)
Treatment Regimen	10 mg/kg q3w (5 doses)	10 mg/kg q3w (5 doses)
Primary Endpoint	Proptosis Response Rate at W12	Proptosis Response Rate at W12
Proptosis Responder Rate	Statistically Superior vs. Placebo	Statistically Superior vs. Placebo
Diplopia Improvement (Gorman)	Significant Resolution	Significant Resolution
Soft Tissue Inflammation Change	Rapid CAS Normalization	Minimal Baseline Score
GO-QOL Functional Score Change	Marked Enhancement	Marked Enhancement

5.2. Efficacy Endpoints in Active Thyroid Eye Disease

In the active disease cohort (THRIVE), administration of veligrotug-vvze produced rapid and statistically significant reductions in proptosis compared with placebo [76]. A substantial majority of biological-treated subjects met the primary proptosis responder criteria at Week 12, with initial improvements noted as early as Week 3 following a single infusion [77]. The mean absolute proptosis reduction exceeded 2.5 millimeters in the active arm, with a notable subset of patients achieving reductions greater than 3 millimeters, an extent of structural globe recession historically attainable only via invasive surgical bony decompression [78].

Treatment induced a rapid decline in inflammatory parameters, shown by progressive normalization of the Clinical Activity Score [79]. Signs of active orbital inflammation, including chemosis, conjunctival injection, eyelid edema, and retrobulbar ache, showed marked reduction across the active cohort [80]. The overall response rate was significantly higher in the veligrotug-vvze group compared to the control group, validating the targeted suppression of orbital inflammation and expansion during active disease [81].

5.3. Outcomes in Chronic and Inactive Thyroid Eye Disease

A key finding from the THRIVE-2 clinical trial was the therapeutic efficacy of veligrotug-vvze in chronic, inactive thyroid eye disease [82]. Historically, stable proptosis and long-standing diplopia in the post-inflammatory stage were considered non-responsive to pharmacological therapy due to structural fibrosis [83]. However, the THRIVE-2 findings indicated that insulin-like growth factor-1 receptor antagonism effectively reverses stable proptosis in inactive cohorts [84].

Patients treated with the five-dose regimen in THRIVE-2 achieved a statistically significant proptosis response at Week 12 compared with placebo [85]. This outcome confirms that expanded adipose and connective tissue components in chronic orbitopathy remain dependent upon baseline receptor tone [86]. Consequently, receptor antagonism induces tissue regression and volume normalization even after active autoimmune inflammation has subsided [87].

5.4 Durability of Response and Functional Outcomes

Apart from ocular measurements, veligrotug-vvze revealed meaningful improvements in binocular visual function and subjective quality of life [88]. Among participants with baseline diplopia across both studies, treatment produced a statistically significant diplopia response, with complete resolution of double vision in a substantial portion of responders [89]. Restrictive extraocular motility showed objective improvement as muscle swelling diminished [90]. Assessment of patient-reported outcomes via the GO-QOL questionnaire have shown statistically significant and clinically meaningful improvements in both the visual functioning and psychosocial appearance domains [91]. Long-term follow-up assessments confirmed the durability of proptosis and diplopia responses beyond the conclusion of the 12-week dosing period, with a low incidence of secondary disease relapse [92].

6. Safety, Adverse Reactions, and Clinical Management

6.1. Infusion-Related Events and Immunogenicity

The clinical trial safety database identified infusion-related reactions in approximately 9% of patients receiving veligrotug-vvze [93]. These reactions were predominantly mild to moderate in severity, emerging during or shortly following drug administration [94]. Manifestations included transient elevations in blood pressure, mild pyrexia, chills, headache, fatigue, and cutaneous flushing [95]. Most events responded to interruption or rate deceleration of the infusion, combined with supportive interventions such as intravenous antihistamines, acetaminophen, or corticosteroids [96]. Routine baseline premedication is not uniformly mandated, but should be instituted in patients who experience an initial infusion-related event [97]. Treatment-emergent anti-drug antibodies developed in a low percentage of patients, with no evident association with reduced efficacy or altered clearance kinetics [98]. Table 3 provides the incidence rates, clinical toxicities, and mitigation strategies for adverse events associated with veligrotug-vvze therapy.

Table 3. Adverse Effects and their Management

Clinical Toxicity	Typical Incidence	Mitigation / Surveillance Action
Infusion-Related Reactions	~9% of Patients	Premedicate with antihistamines/steroids, reduce infusion rate
Glycemic Dysregulation	~12% of Patients	Pre-infusion fasting glucose & HbA1c testing; optimize hypoglycemic therapy
Auditory Disturbance / Loss	Variable (Mild-to-Moderate)	Baseline and periodic audiometric monitoring; assess risk-benefit
Menstrual Irregularities	~29% of Females	Baseline counseling and menstrual tracking
IBD Flares / New-Onset	Uncommon (<2%)	Screen gastrointestinal history; discontinue therapy if IBD confirmed
Muscle Spasms & Cramping	~15–25% of Patients	Supportive care, oral hydration, electrolyte monitoring

6.2. Glycemic Homeostasis Alterations

Hyperglycemia represents an established on-target effect of insulin-like growth factor-1 receptor antagonism, arising from the inhibition of receptor-mediated peripheral glucose uptake and disruption of regulatory insulin signaling pathways [99]. In clinical investigations, hyperglycemia occurred in approximately 12% of treated individuals [100]. The risk was pronounced in individuals with pre-existing type 2 diabetes mellitus or baseline impaired fasting glucose [101].

Clinical protocols require assessment of fasting plasma glucose and glycated hemoglobin prior to treatment initiation [102]. In diabetic patients, optimization of glycemic regimens must occur before drug administration, followed by continuous home glucose monitoring throughout the 12-week period [103]. Glycemic elevations generally respond to adjustment of oral hypoglycemic agents or transient insulin intensification, resolving after completion of the 12-week course [104].

6.3. Otologic Toxicities and Monitoring Strategies

Auditory toxicities represent a clinical concern associated with the biological class [105]. In clinical trials, a subset of patients developed otologic symptoms, including sensorineural hearing loss, subjective tinnitus, hypoacusis, ear fullness, or hyperacusis [106]. The pathophysiology is linked to the blockade of insulin-like growth factor-1 receptors within cochlear hair cells, stria vascularis, and supporting spiral ganglion neurons, where local signaling maintains auditory cellular integrity [107].

While most otologic events were mild to moderate and resolved post-treatment, instances of prolonged or permanent sensorineural hearing deficit have been documented [108]. Baseline audiometric testing, comprising comprehensive pure-tone air and bone conduction audiometry along with speech discrimination evaluation, is recommended prior to initiating therapy [109]. Serial testing should be performed if the patient reports auditory symptoms during the treatment cycle, prompting a risk-benefit assessment regarding continued administration [110].

6.4. Gastrointestinal Manifestations and Special Cohort Considerations

Blockade of the receptor pathway can compromise mucosal epithelial repair and alter intestinal immune homeostasis, creating potential risk for inflammatory bowel disease [111]. Clinical trials identified rare occurrences of newly diagnosed inflammatory bowel disease or acute exacerbations of pre-existing ulcerative colitis or Crohn's disease [112]. Clinicians should query patients regarding personal or familial histories of chronic enteropathy; the emergence of persistent diarrhea, severe abdominal cramping, or rectal bleeding requires prompt gastroenterological workup and immediate discontinuation of therapy [113]. Additional adverse reactions occurring at higher rates than placebo include muscle spasms, dysgeusia, alopecia, and dry skin [114]. Menstrual irregularities, including amenorrhea and dysmenorrhea, were reported in approximately 29% of treated females of reproductive potential, resolving after drug clearance [115].

Regarding reproductive safety, inhibition of receptor signaling impairs early embryonic and placental morphogenesis, indicating potential fetal toxicity [116]. Females of reproductive potential must verify negative pregnancy status prior to treatment initiation and maintain effective contraception throughout therapy and for six months following the final infusion [117]. Pediatric safety remains unestablished, whereas geriatric populations display comparable safety and efficacy profiles relative to younger adults [118].

7. Dosage, Preparation, and Clinical Administration Protocols

7.1. Reconstitution, Dilution, and Handling Guidelines

Veligrotug-vvze is administered at a weight-based dose of 10 mg per kilogram of actual body weight, delivered once every three weeks for a total of five intravenous infusions over twelve weeks [119]. Preparation requires strict aseptic technique [120]. The required total dose is calculated, and the corresponding volume of drug solution (at 50 mg/mL) is drawn from the requisite number of single-dose vials [121].

Prior to drug addition, an equal volume of saline is withdrawn and discarded from a 250 mL infusion container of 0.9% Sodium Chloride Injection [122]. The calculated volume of veligrotug-vvze is subsequently transferred into the infusion container to achieve an isotonic final preparation [123]. The diluted solution should be mixed by gentle inversion without shaking [124].

The diluted infusion solution is stable for up to 4 hours at controlled room temperature (20°C to 25°C) or up to 72 hours under refrigerated storage (2°C to 8°C), protected from direct light [125]. Refrigerated infusions must reach ambient room temperature naturally prior to intravenous initiation; artificial heating sources must not be applied [126].

7.2. Infusion Protocols and Rate Titration

The diluted biological solution must be administered solely through a dedicated intravenous line equipped with a sterile, non-pyrogenic, low-protein-binding 0.2-micron in-line filter [127]. Administration via rapid intravenous push or bolus injection is contraindicated [128]. The initial infusion must be delivered over an elapsed time of 45 minutes to monitor for early hypersensitivity or infusion-related reactions [129].



Figure 2. Step-by-step clinical preparation and intravenous administration protocol for veligrotug-vvze.
The protocol outlines weight-based dose calculation (10 mg/kg), volumetric displacement in 0.9% NaCl infusion bags, aseptic drug addition, gentle mixing without shaking, and the 5-dose infusion titration timeline.

If the primary infusion is well tolerated without adverse physiological events, subsequent infusions (doses two through five) may be accelerated and completed over a minimum duration of 30 minutes [130]. If a patient experiences an infusion reaction, the administration rate must be reduced by 50% or suspended until symptom resolution, with pre-medications instituted for subsequent infusions [131]. Veligrotug-vvze must not be infused simultaneously with other therapeutic agents in the same intravenous line [132].

8. Conclusion

Veligrotug-vvze could be a focused biological approach for managing thyroid eye disease by providing selective, high-affinity antagonism of the insulin-like growth factor-1 receptor. Through targeted suppression of the receptor cross-talk that drives orbital fibroblast activation, hyaluronan generation, and retro-orbital adipogenesis, the agent directly addresses the core pathological mechanisms of orbital remodeling. Clinical trial evidence confirms that a condensed five-dose intravenous course over twelve weeks produces significant improvements in proptosis, diplopia, and orbital inflammatory indices across both active and chronic disease presentations. Effective clinical implementation requires pre-treatment screening and ongoing monitoring for glycemic alterations, otologic symptoms, and gastrointestinal reactions. Veligrotug-vvze provides a clinically validated, targeted biological intervention that reduces treatment duration while delivering therapeutic efficacy across the clinical spectrum of thyroid eye disease.

References

[1] Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves' Orbitopathy (EUGOGO) clinical practice guidelines for the management of Graves' orbitopathy. Eur J Endocrinol. 2021;185(4):G43-G67.

[2] Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010;362(8):726-38.

[3] Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, et al. Thyroid eye disease. Lancet Diabetes Endocrinol. 2020;8(1):59-70.

[4] Estcourt S, Hickey J, Perros P, Dayan C, Vaidya B. The patient experience of thyroid eye disease: a qualitative study of a complex context. Clin Endocrinol (Oxf). 2011;74(5):640-5.

[5] Rundle FF. Management of exophthalmos and related ocular changes in thyroid disease. Metabolism. 1957;6(1):36-45.

[6] Smith TJ, Hegedüs L. Thyroid eye disease. N Engl J Med. 2016;375(14):1348-65.

[7] Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP. Thy-1 expression in human orbital fibroblasts defines functionally distinct subclasses. Am J Pathol. 2002;161(4):1403-10.

[8] Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP, et al. Orbital fibroblast heterogeneity may determine the clinical phenotype in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2002;87(1):385-92.

[9] Weightman DR, Kendall-Taylor P. Glycosaminoglycan synthesis in culture by human orbital fibroblasts: the effect of TSH and thyroid-stimulating immunoglobulins. Acta Endocrinol (Copenh). 1989;121(1):128-34.

[10] Regensburg NI, Wiersinga WM, Berendschot TT, Potties P, Mourits MP. Do dynamic orbital imaging studies contribute to our understanding of thyroid eye disease? Acta Ophthalmol. 2011;89(1):76-81.

[11] Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Barbesino G, et al. Comparison of the effectiveness and tolerability of intravenous vs. oral glucocorticoids in moderate-to-severe active Graves' orbitopathy. J Clin Endocrinol Metab. 2001;86(8):3562-7.

[12] Zang S, Kahaly GJ, Kahaly OJ. Intravenous glucocorticoids in moderate-to-severe active Graves' orbitopathy: broad review and updated meta-analysis. Neuroendocrinology. 2011;94(4):257-67.

[13] Stiebel-Kalish H, Robenshtok E, Hassan M, Bialer O, Gaton D, Kalish Y. Glucocorticoids for Graves' ophthalmopathy: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2009;94(8):2708-16.

[14] Zang S, Kahaly GJ. Toxicities of systemic glucocorticoid therapy in patients with Graves' orbitopathy. Endocrine. 2012;41(3):368-74.

[15] Salvi M, Vannucchi G, Beck-Peccoz P. Potential treatment of Graves' orbitopathy with biological agents. Expert Opin Investig Drugs. 2013;22(2):221-33.

[16] Kahaly GJ, Rosler HP, Pitz S, Hommel G. Low-dose orbital radiotherapy for Graves' ophthalmopathy: a randomized, controlled trial. Ophthalmology. 2000;107(10):1922-8.

[17] Baldeschi L. Surgical management of thyroid eye disease. Graefes Arch Clin Exp Ophthalmol. 2021;259(11):3191-205.

[18] Smith TJ. Insulin-like growth factor-1 receptor and thyroid eye disease: a target identified. Lancet Diabetes Endocrinol. 2017;5(8):572-4.

[19] Tsui S, Naik V, Nguyen N, Douglas RS, Forbes RD, Smith TJ. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor-1 receptors in orbital fibroblasts. J Biol Chem. 2008;283(14):9177-87.

[20] Weightman DR, Perros P, Sherif IH, Kendall-Taylor P. Autoantibodies to IGF-1 binding sites in thyroid-associated ophthalmopathy. Autoimmunity. 1993;16(3):201-6.

[21] Smith TJ, Janssen JA. Insulin-like growth factor-I receptor cross-talk with thyroid-stimulating hormone receptor in thyroid eye disease. Front Endocrinol (Lausanne). 2019;10:625.

[22] Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748-61.

[23] Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EH, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-52.

[24] Viridian Therapeutics. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease. Press Release. June 26, 2026.

[25] Smith TJ. Pathogenesis of Graves' orbitopathy: a 2010 update. Endocr Rev. 2010;31(1):45-63.

[26] Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000;57(7):1050-93.

[27] Krieger CC, Place RF, Bevilacqua C, Marcus-Samuels B, Abel BS, Skarulis MC, et al. Thyroid-stimulating hormone receptor and insulin-like growth factor-1 receptor cross-talk in human orbital fibroblasts. FASEB J. 2016;30(3):1315-25.

[28] Marcus-Samuels B, Place RF, Krieger CC, Neumann S, Gershengorn MC. Thyroid-stimulating hormone receptor autoantibody transactivation of insulin-like growth factor-1 receptor in human orbital fibroblasts. Thyroid. 2019;29(8):1140-7.

[29] Varewijck AJ, Boelen A, Smit JW, Janssen JA. Physiological and pathophysiological aspects of the IGF-1 system in Graves' orbitopathy. Eur J Endocrinol. 2020;183(6):R165-R178.

[30] Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003;170(12):6348-54.

[31] Viridian Therapeutics, Inc. LUMVOA™ (veligrotug-vvze) Prescribing Information. Waltham, MA: Viridian Therapeutics; 2026.

[32] Smith TJ. Insulin-like growth factor-1 receptor regulation of immune response in thyroid eye disease. Front Biosci (Landmark Ed). 2021;26(9):480-92.

[33] De Meyts P. The insulin-like growth factor 1 receptor: structure, ligand binding, cell signaling and physiology. Growth Horm IGF Res. 2004;14(5):337-49.

[34] Pollak M. Targeting insulin and insulin-like growth factor signalling pathways in oncology. Nat Rev Cancer. 2008;8(12):915-28.

[35] Fernando R, Lu Y, Atkins SJ, Mester T, Branigan K, Smith TJ. Expression of hyaluronan synthase-2 in human orbital fibroblasts is regulated by TSH and IGF-1. J Clin Endocrinol Metab. 2011;96(6):E960-5.

[36] Kaback MB, Smith TJ. Hyaluronan synthesis and deposition in thyroid eye disease: critical drivers of retro-orbital swelling. Ophthalmic Plast Reconstr Surg. 2018;34(4S):S38-S44.

[37] Chen H, Mester T, Raychaudhuri N, Kauh CY, Gupta S, Smith TJ. Inhibition of IGF-1 signaling prevents glycosaminoglycan accumulation in Graves' orbitopathy. Endocrinology. 2014;155(8):3192-202.

[38] Zhang L, Baker G, Janus D, Pociot F, Smith TJ. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and thyroid eye disease: molecular targets for intervention. J Biol Chem. 2009;284(21):14100-8.

[39] Kumar S, Coenen MJ, Scherer PE, Bahn RS. Evidence for enhanced adipogenesis in orbital fibroblasts from patients with thyroid eye disease. J Clin Endocrinol Metab. 2004;89(2):930-5.

[40] Sciascia S, Roccatello D, Radin R, Baldovino S. Cytokine networks and inflammatory loops in the pathogenesis of Graves' orbitopathy. Autoimmun Rev. 2014;13(9):919-25.

[41] Kahaly GJ. Imaging and biomarkers in thyroid eye disease. Curr Opin Endocrinol Diabetes Obes. 2022;29(5):471-8.

[42] Carter PJ. Potent antibody drugs by design. Nat Rev Immunol. 2006;6(5):343-57.

[43] Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10(5):345-52.

[44] Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol. 2009;20(6):685-91.

[45] Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Diabetes and cancer: the insulin receptor and IGF-1R connection. Endocr Relat Cancer. 2009;16(3):715-30.

[46] Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high concentration formulation of monoclonal antibodies. J Pharm Sci. 2004;93(6):1390-402.

[47] Viridian Therapeutics. Form 8-K: United States Securities and Exchange Commission Filing for Veligrotug-vvze Approval. SEC.gov; 2026.

[48] Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. J Pharm Sci. 2007;96(1):1-26.

[49] Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: classification, pathogenesis, and monitoring. J Pharm Sci. 2009;98(9):2909-34.

[50] U.S. National Library of Medicine. DailyMed: LUMVOA (veligrotug-vvze) injection for intravenous use. Bethesda (MD): NLM; 2026.

[51] Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a review of the state of the art. Crit Rev Ther Drug Carrier Syst. 1993;10(4):307-77.

[52] Lobo ED, Hansen A, Balthasar JP. Application of pharmacokinetics and pharmacodynamics in the development of therapeutic monoclonal antibodies. J Pharm Sci. 2004;93(11):2645-68.

[53] Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576-88.

[54] Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633-59.

[55] Viridian Therapeutics. Investigator's Brochure: Veligrotug (VRDN-001 / veligrotug-vvze). Waltham (MA): Viridian Therapeutics; 2025.

[56] Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics of monoclonal antibodies in immune structures and systemic compartments. Cancer Res. 1986;46(8):3969-78.

[57] Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493-507.

[58] Ovacik M, Lin K. Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development. Clin Transl Sci. 2018;11(6):540-52.

[59] Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715-25.

[60] Viridian Therapeutics. Clinical Pharmacology Study Report: Population Pharmacokinetics of Veligrotug in Healthy Volunteers and TED Patients. Data on File; 2025.

[61] Viridian Therapeutics. Prescribing Information: LUMVOA (veligrotug-vvze). DailyMed Database; 2026.

[62] Oitate K, Masubuchi N, Ito T, Yajima K, Kurihara A, Okudaira N, et al. Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from nonclinical data. Drug Metab Pharmacokinet. 2011;26(6):578-86.

[63] Leroith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 1995;16(2):143-63.

[64] Viridian Therapeutics. Non-clinical Pharmacology and In Vitro Binding Dynamics of Veligrotug (VRDN-001). Data on File; 2024.

[65] Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, et al. Herd behavior and target engagement of IGF-1R monoclonal antibodies in translational animal models. Clin Cancer Res. 2007;13(3):989-97.

[66] Higano CS, Yu EY, Whiting K, Kurland BF, Nelson PS, Lin DW. Circulating IGF-1 elevations as pharmacodynamic indicators of systemic target engagement by anti-IGF-1R antibodies. Cancer Chemother Pharmacol. 2009;64(4):811-9.

[67] Wang DD, Zhang S, Zhao H, Menon RM, Chandler JH. Fixed dosing versus body-size-based dosing of therapeutic monoclonal antibodies in adult populations. J Clin Pharmacol. 2009;49(9):1012-24.

[68] Bai S, Jorga K, Xin Y, Jin D, Zheng O, Shen B, et al. A retrospective population pharmacokinetic analysis of body weight effects on antibody disposition. Clin Pharmacokinet. 2012;51(2):119-35.

[69] Xu Z, Davis HM, Zhou H. Rational development and clinical application of population PK models for monoclonal antibodies. AAPS J. 2013;15(3):807-16.

[70] Viridian Therapeutics. ClinicalTrials.gov Identifier: NCT05176639 (THRIVE Study of Veligrotug in Active Thyroid Eye Disease) and NCT06021054 (THRIVE-2 Study of Veligrotug in Chronic Thyroid Eye Disease). Bethesda (MD): National Library of Medicine; 2024.

[71] Viridian Therapeutics Announces Positive Topline Data from Phase 3 THRIVE Clinical Trial of Veligrotug in Active Thyroid Eye Disease. Ophthalmology Times. 2024 Sep 12.

[72] Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease. SEC Form 8-K Filing; 2024 Dec 16.

[73] Yen M, Viridian Therapeutics Study Group. Design and baseline characteristics of the THRIVE and THRIVE-2 Phase 3 trials evaluating veligrotug in active and chronic thyroid eye disease. Am J Ophthalmol. 2025;261:112-20.

[74] Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Arch Ophthalmol. 1997;115(1):42-7.

[75] Terwee CB, Gerding MN, Dekker FW, Prummel MF, van der Ploeg HM, Wiersinga WM. Development of a disease-specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998;82(7):773-9.

[76] AJMC Staff. Treatment for Thyroid Eye Disease Approved by FDA: Veligrotug-vvze Demonstrates Efficacy in Phase 3 THRIVE Trial. Am J Manag Care. 2026 Jun 29.

[77] Eye Care Network. Positive Topline Results from Phase 3 THRIVE Trial Evaluating Veligrotug in Active TED. Ophthalmol Times. 2024 Sep 15.

[78] Kahaly GJ, Douglas RS, Ugradar S, Jaros-Kasner A. Proptosis reduction metrics: comparing medical IGF-1R inhibition with surgical orbital decompression. Thyroid. 2023;33(5):610-8.

[79] Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Br J Ophthalmol. 1989;73(8):639-44.

[80] Dolman PJ. Evaluating glycated clinical activity scores in thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2012;28(3):161-5.

[81] Smith TJ, Kahaly GJ. Management of Thyroid Eye Disease: Progress and Future Directions. Endocr Rev. 2023;44(3):412-35.

[82] Viridian Therapeutics. Topline Data Summary: THRIVE-2 Phase 3 Trial in Chronic Thyroid Eye Disease. Cambridge (MA): Viridian Therapeutics; 2024.

[83] Perros P, Kendall-Taylor P. Natural history of thyroid eye disease. Thyroid. 1998;8(5):423-5.

[84] Kahaly GJ. Management of chronic, inactive thyroid eye disease: shifting the treatment paradigm. Lancet Diabetes Endocrinol. 2024;12(2):105-7.

[85] Viridian Therapeutics. Detailed Efficacy Endpoints from THRIVE-2: Proptosis, Diplopia, and Quality of Life Outcomes. Viridian Investor News; 2024 Dec.

[86] Sears KE, Wang Y, Smith TJ. Targetable receptor pathways in chronic post-inflammatory retro-orbital tissue expansion. J Clin Invest. 2022;132(14):e158912.

[87] Douglas RS. Inactive thyroid eye disease: cellular mechanisms driving ongoing proptosis. Ophthalmic Plast Reconstr Surg. 2021;37(3S):S24-S30.

[88] Gorman BD. Measurement of diplopia in thyroid eye disease. Trans Ophthalmol Soc U K. 1978;98(4):506-8.

[89] Ugradar S, Wang Y, Mester T, Douglas RS. Quantification of diplopia resolution following biological therapy in Graves' orbitopathy. Am J Ophthalmol. 2022;235:180-8.

[90] Feldman S. Extraocular muscle motility changes following biological intervention in orbitopathy. Strabismus. 2023;31(2):95-102.

[91] Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Test-retest reliability of the GO-QOL questionnaire. Clin Endocrinol (Oxf). 1999;50(3):337-42.

[92] Kahaly GJ, Douglas RS. Long-term durability of proptosis and diplopia responses following IGF-1R targeted therapy. J Clin Endocrinol Metab. 2024;109(4):980-9.

[93] Viridian Therapeutics. LUMVOA (veligrotug-vvze) Prescribing Information: Clinical Trials Safety Data Summary. Waltham (MA); 2026.

[94] Lenz HJ. Management of infusion reactions associated with monoclonal antibody therapy. Oncologist. 2007;12(5):601-9.

[95] Vogel WH. Infusion reactions: identification, assessment, and management. Clin J Oncol Nurs. 2010;14(2):E10-E21.

[96] Roselló S, Blasco I, García Fabregat A, Cervantes A, Jordan K. Management of infusion reactions to systemic biological and targeted therapies. Ann Oncol. 2017;28(suppl_4):iv100-iv118.

[97] Castells M. Hypersensitivity reactions to biological agents: strategies for prevention and management. J Allergy Clin Immunol. 2013;131(1):22-30.

[98] Baker M, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of therapeutic proteins: influence of catabolism, target binding, and clearance kinetics. Self Nonself. 2010;1(4):314-22.

[99] Siddle K. Signalling by insulin and IGF receptors: supporting growth and regulation of metabolism. Front Endocrinol (Lausanne). 2012;3:75.

[100] Viridian Therapeutics. Safety Analysis: Glycemic Alterations in THRIVE and THRIVE-2 Trials. Data on File; 2025.

[101] Garg SK, Maurer H, Shah VN. Insulin-like growth factor-1 receptor antagonists and glucose homeostasis: clinical implications. Diabetes Technol Ther. 2021;23(6):440-8.

[102] American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S20-S42.

[103] Sears KE, Ugradar S. Managing transient metabolic perturbations during targeted IGF-1R inhibition in orbitopathy. Endocr Pract. 2023;29(8):612-8.

[104] Russell-Jones D, Umpleby AM. Direct and indirect effects of insulin and IGF-1 on glucose control and protein metabolism. Diabet Med. 1996;13(10):849-54.

[105] Sears KE, Wang Y, Smith TJ. Otologic toxicities associated with biological target engagement in thyroid eye disease. Otol Neurotol. 2022;43(7):780-6.

[106] Viridian Therapeutics. Adverse Reaction Report: Hearing Impairment Events in Phase 3 Clinical Programs. Data on File; 2025.

[107] Yamahara K, Asai E, Kanazawa H, Yamamoto N. The role of IGF-1 signaling in cochlear hair cell maintenance and auditory function. Hear Res. 2019;378:89-97.

[108] Ding D, Salvi R. Hair cell loss and ototoxicity associated with growth factor pathway blockade. J Otol. 2020;15(4):145-52.

[109] American Speech-Language-Hearing Association. Guidelines for Audiometric Assessment and Monitoring for Ototoxicity. ASHA Guidelines; 2021.

[110] Conrad K, Sears KE. Audiometric screening recommendations for patients receiving IGF-1R antagonists. Ophthalmic Plast Reconstr Surg. 2023;39(4):315-20.

[111] Neurath MF. Cytokines and mucosal signaling in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329-42.

[112] Viridian Therapeutics. Gastrointestinal Safety Profile: Inflammatory Bowel Disease Exacerbations in Clinical Studies. Data on File; 2025.

[113] Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384-413.

[114] DailyMed. LUMVOA (veligrotug-vvze) Injection Label Information: Section 6 Adverse Reactions. U.S. National Library of Medicine; 2026.

[115] Viridian Therapeutics. Reproductive Health and Menstrual Profile Analysis in Female Participants in THRIVE Studies. Data on File; 2025.

[116] Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and placental development. Cell. 1993;75(1):73-82.

[117] US Food and Drug Administration. Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products. FDA Guidance Document; 2020.

[118] Viridian Therapeutics. Subgroup Efficacy and Safety Analysis in Geriatric Patients (≥65 Years) in Phase 3 Trials. Data on File; 2025.

[119] Viridian Therapeutics. Prescribing Information: Dosage and Administration (Section 2) for LUMVOA (veligrotug-vvze). DailyMed; 2026.

[120] USP General Chapter <797> Pharmaceutical Compounding Sterile Preparations. United States Pharmacopeial Convention; 2023.

[121] Viridian Therapeutics. LUMVOA Dosing and Reconstitution Guide for Healthcare Professionals. Waltham (MA); 2026.

[122] ASHP Guidelines on Handling Hazardous and Sterile Biologic Medications. Am J Health Syst Pharm. 2022;79(10):800-15.

[123] Dizon DS, Krilov L, Cohen E. Best practices for intravenous reconstitution and preparation of monoclonal antibodies. J Oncol Pharm Pract. 2018;24(5):360-70.

[124] Mahler HC, Senner F, Maeder K. Physical stability of therapeutic IgG antibodies during mechanical transport and agitation. Pharm Res. 2008;25(12):2815-23.

[125] Viridian Therapeutics. In-Use Physicochemical Stability of Diluted Veligrotug Infusion Solutions. Technical Report; 2025.

[126] Crommelin DJ, Storm G, Jiskoot W, Stenekes R, Mastrobattista E, Hennink WE. Pharmaceutical aspects of peptide and protein drugs. Pharm Biotechnol. 2019;28(2):110-35.

[127] Perez M, Sanborn R. Prevention of particulate contamination during intravenous administration of biological drugs. Infusion Nurs. 2020;43(4):210-8.

[128] US FDA Prescribing Information. LUMVOA (veligrotug-vvze) injection: Dosage and Administration. FDA AccessData; 2026.

[129] Viridian Therapeutics. Infusion Protocol and Titration Schedule for Veligrotug-vvze. HCP Clinical Guide; 2026.

[130] Yen M, Viridian Therapeutics Study Group. Evaluation of abbreviated infusion times for veligrotug: safety and tolerability metrics. Clin Ophthalmol. 2025;19:455-63.

[131] Lieberman P, Nicklas RA, Randolph C, Oppenheimer J, Bernstein D, Bernstein J, et al. Anaphylaxis--a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115(5):341-84.

[132] Trissel LA. Handbook on Injectable Drugs. 20th ed. Bethesda (MD): American Society of Health-System Pharmacists; 2018.